Aktis Oncology Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, that develops targeted radiopharmaceuticals for the treatment of solid tumors. The company utilizes a proprietary miniprotein radioconjugate platform designed to deliver alpha-emitting radioisotopes directly to cancer cells while limiting exposure to healthy tissue.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
6,497
1,487
—
—
Gross Profit
6,497
1,487
—
—
Selling, General & Administrative Expenses
13,730
12,583
8,875
5,462
Research & Development Expenses
67,451
40,954
25,919
14,302
Operating Profit
(74,684)
(52,050)
(34,794)
(19,764)
Interest and Investment Income
11,009
8,103
5,377
1,647
Non-Operating Income
(56)
(33)
776
188
Total Non-Operating Income
10,953
8,070
6,153
1,835
Income Before Provision for Income Taxes
(63,731)
(43,980)
(28,641)
(17,929)
Consolidated Net Income
(63,731)
(43,980)
(28,641)
(17,929)
Net Income Attributable to Common Shareholders
(63,731)
(43,980)
(28,641)
(17,929)
Basic EPS
-78.34
-62.46
-46.56
-34.66
Diluted EPS
-78.34
-62.46
-46.56
-34.66
Basic Weighted Average Shares Outstanding
814
704
615
517
Diluted Weighted Average Shares Outstanding
814
704
615
517
Shares Outstanding
915
781
650
569
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
37,784
37,159
29,513
128,597
Short-Term Investments
189,003
260,009
68,349
—
Total Cash and Cash Equivalents
226,787
297,168
97,862
128,597
Other Current Assets
3,523
3,685
2,342
3,884
Total Current Assets
230,310
300,853
100,204
132,481
Net Property, Plant & Equipment
27,246
20,871
20,924
4,865
Other Long-Term Assets
7,329
4,457
1,227
976
Total Assets
264,885
326,181
122,355
138,322
Accounts Payable
1,737
1,918
957
490
Accrued Expenses
9,522
6,331
3,752
3,931
Current Portion of Leases
1,315
1,296
1,528
854
Unearned Revenue
18,662
9,277
—
—
Total Current Liabilities
31,236
18,822
6,237
5,275
Leases
10,233
10,714
11,874
921
Other Long-Term Liabilities
36,156
51,039
500
1,306
Total Long-Term Liabilities
46,389
61,753
12,374
2,227
Total Liabilities
77,625
80,575
18,611
7,502
Additional Paid-in Capital
10,373
4,906
2,465
982
Accumulated Other Comprehensive Income
42
124
82
—
Retained Earnings
(156,564)
(92,833)
(48,853)
(20,212)
Total Common Shareholders' Equity
(146,149)
(87,803)
(46,306)
(19,230)
Minority Interests and Other
333,409
333,409
150,050
150,050
Total Shareholders' Equity
187,260
245,606
103,744
130,820
Total Liabilities and Shareholders' Equity
264,885
326,181
122,355
138,322
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(63,731)
(43,980)
(28,641)
(17,929)
Depreciation & Amortization
2,329
1,575
1,120
445
Share-Based Compensation Expense
5,131
2,260
1,478
698
Other Adjustments
(4,624)
(4,073)
(3,946)
(200)
Changes in Accounts Payable
(44)
360
659
(1)
Changes in Accrued Expenses
2,200
2,152
(227)
2,537
Changes in Unearned Revenue
(5,498)
58,513
—
—
Changes in Other Operating Activities
110
(2,045)
(447)
(3,675)
Cash from Operating Activities
(64,127)
14,762
(30,004)
(18,125)
Capital Expenditure
(9,584)
(2,862)
(3,764)
(2,307)
Proceeds from Sale of Property, Plant & Equipment
—
—
57
—
Purchases of Investments
(193,868)
(288,396)
(145,806)
—
Proceeds from Sale of Investments
269,416
100,858
80,685
—
Cash from Investing Activities
65,964
(190,400)
(68,828)
(2,307)
Issuance of Common Shares
336
179
—
—
Net Issuance / (Repurchases) of Common Shares
336
179
—
—
Issuance of Preferred Shares
—
185,000
—
120,135
Net Issuance / (Repurchases) of Preferred Shares
—
185,000
—
120,135
Other Financing Activities
(1,548)
(1,895)
—
(151)
Cash from Financing Activities
(1,212)
183,284
—
119,984
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash